Sangamo price target raised to $27 from $22 at JMP Securities JMP Securities increased its price target on Sangamo after meeting with the company's clinical and scientific team. The firm increased its estimate of the likelihood of the company's HIV program succeeding to 60% from 50%. JMP Securities thinks the company is clicking on all cylinders, and reiterates an Outperform rating on the shares.
News For SGMO From The Last 14 Days
Check below for free stories on SGMO the last two weeks.